Is Vaginal Estrogen Safe After Endometrial Cancer?
In this article
New-generation data shed light on how treatments that improve quality of life affect the risk of recurrence.
25 Thousand Women and 6 Years of Follow-Up
The study was conducted using data from the TriNetX US Collaborative Network covering 2005-2023. A large population of 25408 women diagnosed with endometrial cancer at ages 18-51 was screened. Using “Propensity Score Matching”, the researchers created two homogeneous cohorts of women who received vaginal estrogen and those who did not. This methodology increased the reliability of the results by minimizing the effects of confounding factors such as age, stage, comorbidities, and patterns of healthcare use.
During 1 to 6 years of follow-up, no significant association was found between vaginal estrogen use and cancer recurrence (HR: 0.87; 95% CI, 0.60-1.27). These data support the oncological safety of local VET.
Despite the large number of symptomatic patients, only 5.6% of survivors were prescribed vaginal estrogen. This shows that safety concerns remain a barrier to treatment in clinical practice.
Clinical Findings and Discussion
The study’s findings support previous pharmacokinetic studies showing that systemic absorption of local estrogen is clinically negligible. The mean duration of use of 2 years in patients with symptoms of vaginal atrophy proves that treatment is generally temporary and targeted. However, further prospective randomized controlled studies are needed to fully assess the effects of long-term use (over 5 years).
Clinical Implications for Physicians
- Stage and Grade Analysis: Although the study includes low-risk cases, the decision to use VET in high-grade or advanced-stage tumors must still be individualized.
- Systemic Absorption: It is assumed that local vaginal tablets and creams do not raise circulating estradiol levels beyond menopausal limits.
- Patient Education: The “Shared Decision-Making” process is essential to reduce patients’ fears and improve treatment adherence.
The days when we measured success in cancer treatment only by “survival” times are behind us. Today, we also regard our patients’ post-treatment quality of life, sexual health, and everyday comfort as measures of treatment success.
This study shows, through the data offered by evidence-based medicine, that safe symptom management is possible. Our responsibility as physicians is to share these up-to-date data with our patients and free them not only from cancer but also from the physical limitations that cancer brings to their lives.
Literature and References
- • Hsu, C. D., et al. (2026). "Vaginal Estrogen Therapy Utilization and Endometrial Cancer Recurrence." Menopause. DOI: 10.1097/GME.000000000000XXXX.
- • Norton, A. (Ed.). (2026). "Is Vaginal Estrogen Safe After Endometrial Cancer?" Medscape Medical News, March 4, 2026.
- • American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141: Management of Menopausal Symptoms.
- • European Society of Gynaecological Oncology (ESGO) 2025 Guidelines update.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.